Salipro Biotech Gains European Patent for Novel Method of Membrane Protein Extraction and Library Generation
Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.
Swedish biotech, Salipro Biotech, has been granted a European Patent for its novel method of direct extraction of membrane proteins (DirectMX) and for the generation of libraries with Salipro particles, the company announced in a Feb. 17, 2021 press release.
The “Saposin lipoprotein particles and libraries from crude membranes” patent covers the use of DirectMX from cells or crude membranes to enable drug development of challenging drug targets. Additionally, the generation of libraries with Salipro particles representing the membrane proteome, the particles themselves, and their uses is covered.
“Ever since its inception, DirectMX has had a profound impact on how we accelerate drug discovery with our pharma partners,” said Jens Frauenfeld, CEO, Salipro Biotech in the press release. “Our foundational [intellectual property] covering the Salipro platform technology has already resulted in various patents being granted to Salipro Biotech in the [United States], [European Union], China, and Japan, and this patent will provide additional broad protection for our proprietary platform technology for the stabilization of challenging drug targets.”
Maria Knudsen, business developer, Salipro Biotech, added in the press release, “DirectMX is rapidly becoming established as a key drug discovery platform and we are already partnering with major pharma companies on a range of targets. Further strengthening our patent portfolio will enable us to increase the value of such collaborations as well as moving towards building our own discovery pipeline.”
Source: Salipro Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
